Funder: Pershing Square Philanthropies
Due Dates: December 21, 2026 (Applications open) | February 1, 2027, 5:00 p.m. ET (LOI deadline)
Funding Amounts: $750,000 over three years ($250,000 annually, including indirect costs)
Summary: Supports bold, high-risk, high-reward ovarian cancer research and work in other cancers with potential ovarian cancer impact.
Key Information: Lead investigators without ovarian cancer experience must include a collaborator with that expertise.
Description
The Pershing Square Foundation’s Lotus Award combines its priorities in women’s health and cancer research to address ovarian cancer, an understudied and underfunded disease with limited early-detection and treatment options. It supports investigators already pursuing promising ovarian cancer projects and researchers studying other cancers whose work could advance the field.
The award emphasizes radically innovative, high-risk, high-reward projects that may be too risky for traditional funding. Research can address basic biology, early detection, prevention, immunotherapy, realistic disease models, novel technologies, dormant cells, or translational and therapeutic applications. The Foundation seeks fresh perspectives and collaboration across scientific boundaries, with priority for bold projects aimed at curing the disease.
